Видео ютуба по тегу Biocon Group Growth Outlook

Biocon Biologics CEO: Integration To Boost Value, Balance Sheet & Competitiveness | Business News
Biocon Biologics CEO: Integration To Boost Value, Balance Sheet & Competitiveness | Business News
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Biocon Equity Raise, Anand Rathi AUM Growth, HDFC Bank Valuations & Top Sector Picks | Business News
Biocon Equity Raise, Anand Rathi AUM Growth, HDFC Bank Valuations & Top Sector Picks | Business News
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
CEO of India's Biocon discusses first-quarter results
CEO of India's Biocon discusses first-quarter results
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biocon Income Analysis | Stock Analysis 2025 | Revenue, Profit Trends, EPS Growth & Pharma Outlook
Biocon Income Analysis | Stock Analysis 2025 | Revenue, Profit Trends, EPS Growth & Pharma Outlook
Generics Growth Aided By Other Drugs Besides Liraglutide & API Biz: Biocon | CNBC TV18
Generics Growth Aided By Other Drugs Besides Liraglutide & API Biz: Biocon | CNBC TV18
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
How Biocon Is Driving Market Expansion
How Biocon Is Driving Market Expansion
Kiran Mazumdar Shaw Shares Her Views On Biocon Biologics Acquiring Viatris Biosimilar's Business
Kiran Mazumdar Shaw Shares Her Views On Biocon Biologics Acquiring Viatris Biosimilar's Business
Biocon Gets US FDA Approval for Everolimus Tablets: Key Growth Trigger Explained
Biocon Gets US FDA Approval for Everolimus Tablets: Key Growth Trigger Explained
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Biocon Biologics Q4 Result 2025: PAT Jumps 2.5x, Demand & Price Environment Outlook | Business News
Biocon Biologics Q4 Result 2025: PAT Jumps 2.5x, Demand & Price Environment Outlook | Business News
Biocon Sees Two Segments Driving Its Growth In 2019-20: #Q1WithBQ
Biocon Sees Two Segments Driving Its Growth In 2019-20: #Q1WithBQ
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
Biocon Management On Q1 Result And Growth Strategy For FY22
Biocon Management On Q1 Result And Growth Strategy For FY22
Biocon Ltd concall for Q2FY26 #Bioconconcall #Biocon
Biocon Ltd concall for Q2FY26 #Bioconconcall #Biocon